Literature DB >> 9796277

Effects of concomitant usage of milrinone and catecholamine for weaning from cardiopulmonary bypass.

Y Orime1, M Shiono, H Hata, S Yagi, S Tsukamoto, S Kimura, S Ohmiya, A Sezai, H Yamada, M Obana, Y Sezai.   

Abstract

To estimate the effectiveness of concomitant usage of milrinone and catecholamine for weaning from cardiopulmonary bypass (CPB), a clinical study was made, in elective coronary artery bypass grafting (CABG) cases. 24 consecutive patients underwent elective CABG in our institute. In all cases, moderate hypothermia and cardioplegic(St. Thomas solution) cardiac arrest were performed. In 12 cases, continuous intravenous 0.25 microgram/kg/min of milrinone, 3 micrograms/kg/min of dobutamine (DOB) and dopamine (DOA) as the initial doses, were used concomitantly as inotropic agents (Group-I). The same initial doses of catecholamine (DOB and DOA) as the Group-I were administered in another 12 patients (Group-II). When the pump flow of CPB decreased to a half, these drugs were administered in both groups. Hemodynamic data were measured before CPB, just after operation, 3, 6, 12, 24, 48, and 72 hours after operation. There were no significant differences in aortic and pulmonary artery pressure between both groups. However, cardiac index (CI) of the Group-I demonstrated significantly (p < 0.01) higher values than that of Group-II until 24 hours after surgery. Systemic vascular resistance index (SVRI) of the Group-I demonstrated significantly (p < 0.01) lower value than that of Group-II from 3 to 12 hours after operation. There were no significant differences in oxygen delivery (DO2) and oxygen consumption (VO2) between both groups. These results suggested that concomitant usage of milrinone and low dose catecholamine increased CI and decreased SVRI, and made weaning from CPB very easy, demonstrating excellent hemodynamics. This high potential phosphodiesterase inhibitor may be suitable for not only weaning from CPB but also post-cardiotomy cardiogenic shock.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9796277     DOI: 10.1007/bf03217826

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  20 in total

1.  Amrinone in perioperative low cardiac output syndrome.

Authors:  G Fita; C Gomar; M J Jimenez; M Pacheco; J Mulet; M A Nalda
Journal:  Acta Anaesthesiol Scand       Date:  1990-08       Impact factor: 2.105

2.  Effects of amrinone on cardiac index, venous oxygen saturation and venous admixture in patients recovering from cardiac surgery.

Authors:  R C Prielipp; J F Butterworth; G P Zaloga; P G Robertie; R L Royster
Journal:  Chest       Date:  1991-04       Impact factor: 9.410

3.  Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States.

Authors:  J L Anderson
Journal:  Am Heart J       Date:  1991-06       Impact factor: 4.749

Review 4.  Milrinone and postoperative pulmonary hypertension.

Authors:  R O Feneck
Journal:  J Cardiothorac Vasc Anesth       Date:  1993-04       Impact factor: 2.628

5.  [Hemodynamic effects of amrinone, phosphodiesterase inhibitor, early after coronary artery bypass grafting].

Authors:  T Shibata; S Suehiro; H Minamimura; Y Sasaki; T Ishikawa; K Hattori; H Kinoshita
Journal:  Nihon Kyobu Geka Gakkai Zasshi       Date:  1996-11

6.  Mechanism of the redistribution of renal cortical blood flow during hemorrhagic hypotension in the dog.

Authors:  J H Stein; S Boonjarern; R C Mauk; T F Ferris
Journal:  J Clin Invest       Date:  1973-01       Impact factor: 14.808

7.  Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery.

Authors:  J M Bailey; J H Levy; M Kikura; F Szlam; C C Hug
Journal:  Anesthesiology       Date:  1994-09       Impact factor: 7.892

Review 8.  The concept of a critical oxygen delivery.

Authors:  P T Schumacker; S M Cain
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

9.  Intravenous milrinone following cardiac surgery: I. Effects of bolus infusion followed by variable dose maintenance infusion. The European Milrinone Multicentre Trial Group.

Authors:  R O Feneck
Journal:  J Cardiothorac Vasc Anesth       Date:  1992-10       Impact factor: 2.628

10.  Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure.

Authors:  C S Maskin; L Sinoway; B Chadwick; E H Sonnenblick; T H Le Jemtel
Journal:  Circulation       Date:  1983-05       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.